Advanced Enzyme moves to full ownership of JC Biotech, adds ₹20M to Nutrazyme

What's the deal? Advanced Enzyme TechnologiesDealroom has a profile for this one. Try Dealroom →' board has approved buying the remaining 4.28% of JC Biotech Private LimitedDealroom has a profile for this one. Try Dealroom → from outside shareholders, making it a wholly owned subsidiary, according to a BSE filing. In a separate decision, the board cleared a ₹20 million capital infusion into Advanced Nutrazyme Private LimitedDealroom has a profile for this one. Try Dealroom →.

What's the endgame? JC Biotech was already a subsidiary; acquiring the residual stake eliminates all minority interest and consolidates full ownership. The Nutrazyme funds, an existing wholly owned unit, will be deployed in one or more tranches, giving the parent flexibility on timing.

The signal: Both moves point to Advanced Enzyme tightening control of its subsidiary network — one through full ownership, the other by shoring up finances. Its shares last traded at ₹324.35 on the NSE, down 1.65% from the previous close.

Read more: India Shorts

Image credit: USDAgov